NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical stud ...
Positive allosteric modulators (PAMs) of the muscarinic acetylcholine M4 receptor show potential against schizophrenia because they can enhance endogenous acetylcholine signaling, which in turn may ...
Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.
Ivana Magovčević-Liebisch President and CEO, Dr Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology ...
Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target. | Neurocrine ...
Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and ...
Investing.com -- Neumora Therapeutics Inc (NASDAQ:NMRA) stock jumped 8.4% in premarket trading Monday after the company reported positive preclinical data for its obesity drug candidate and received ...
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
TipRanks on MSN
Neumora Therapeutics Begins Phase 1 Study for NMRA-898
The latest announcement is out from Neumora Therapeutics, Inc. ( ($NMRA) ). On October 27, 2025, Neumora Therapeutics announced the initiation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback